Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

TSHA

Taysha Gene Therapies Inc

Oct 31 • 04:00PM ET

1.69

Dollar change -0.18
Percentage change -9.63	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT CRSP NTLA BLUE QURE EDIT IOVA ADVM SGMO GNFT

| Held by: VTI IWM VXF IWO IBB VTWO IWC FESM VTWG ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.87	Insider Own	22.67%	Shs Outstand	186.96M	Perf Week	-14.21%
Market Cap	346.35M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	2.95%	Shs Float	158.49M	Perf Month	-17.56%
Income	-114.33M	PEG	-	EPS next Q	-0.09	Inst Own	72.81%	Short Float	13.06%	Perf Quarter	-19.52%
Sales	12.87M	P/S	26.91	EPS this Y	61.69%	Inst Trans	20.08%	Short Ratio	13.57	Perf Half Y	-34.50%
Book/sh	0.54	P/B	3.13	EPS next Y	-8.94%	ROA	-81.11%	Short Interest	20.70M	Perf Year	-27.78%
Cash/sh	0.85	P/C	2.00	EPS next 5Y	-	ROE	-318.69%	52W Range	1.27 - 4.32	Perf YTD	-4.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.69%	ROI	-69.36%	52W High	-60.88%	Beta	0.38
Dividend TTM	-	Quick Ratio	5.20	Sales past 5Y	129.39%	Gross Margin	89.73%	52W Low	33.07%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	5.20	EPS Y/Y TTM	62.04%	Oper. Margin	-598.62%	RSI (14)	25.16	Volatility	6.08% 4.41%
Employees	52	Debt/Eq	0.53	Sales Y/Y TTM	34.05%	Profit Margin	-888.18%	Recom	1.09	Target Price	6.41
Option/Short	Yes / Yes	LT Debt/Eq	0.51	EPS Q/Q	76.52%	Payout	-	Rel Volume	1.37	Prev Close	1.87
Sales Surprise	-59.65%	EPS Surprise	42.68%	Sales Q/Q	-53.57%	Earnings	Aug 12 BMO	Avg Volume	1.53M	Price	1.69
SMA20	-14.21%	SMA50	-18.35%	SMA200	-29.21%	Trades		Volume	2,091,666	Change	-9.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$5
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42
Oct-19-20	Initiated	Morgan Stanley	Overweight	$29
Oct-19-20	Initiated	Jefferies	Buy	$34

Show Previous Ratings

Oct-22-24 08:00AM	Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress (GlobeNewswire)
Oct-16-24 03:42PM	Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-14-24 12:00PM	Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-04-24 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 04:55AM	Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5? (Insider Monkey)
08:00AM	Loading…
Sep-26-24 08:00AM	Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress (GlobeNewswire)
Sep-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-24 08:00AM	Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-24 09:14AM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -17.24%
08:36AM	Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:34PM	Loading…
Jun-25-24 06:34PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -7.33%
Jun-18-24 07:30AM	Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome (GlobeNewswire) -26.30%
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-13-24 06:00AM	How to Invest in Penny Stocks in 2024: 3 Best Picks (InvestorPlace) +6.65%
Jun-12-24 07:00AM	Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire)
Jun-07-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:31PM	Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company? (Insider Monkey) +5.54%
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-15-24 03:11AM	Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) +21.01%
May-14-24 08:57PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +7.08%
05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:03PM	Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours (MT Newswires)
04:01PM	Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 04:05PM	Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14 (GlobeNewswire) -5.34%
May-03-24 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:01AM	Loading…
May-02-24 10:01AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks) +6.61%
08:00AM	Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome (GlobeNewswire)
Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks)
Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal) -9.52%
Apr-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 11:19AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript (Insider Monkey) +31.56%
08:01AM	Q4 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.63%
04:01PM	Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Mar-14-24 04:26PM	Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 (GlobeNewswire) -5.31% +7.48%
Mar-01-24 05:08PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.12%
Feb-29-24 08:00AM	Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome (GlobeNewswire) +19.70%
Feb-15-24 04:01PM	Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs (GlobeNewswire) +8.90% +20.13%
Feb-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 08:00AM	Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference (GlobeNewswire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-10-24 08:00AM	Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome (GlobeNewswire) -7.29%
Jan-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-23 07:30AM	Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies (PR Newswire)
Nov-29-23 08:00AM	Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients (GlobeNewswire)
Nov-15-23 02:00PM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript (Insider Monkey) +26.32%
12:52PM	Q3 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:35PM	Taysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com)
04:08PM	Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Nov-07-23 08:00AM	Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14 (GlobeNewswire)
Oct-24-23 08:00AM	Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire)
Oct-10-23 08:00AM	Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire) -5.97%
Sep-26-23 08:00AM	Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome (GlobeNewswire)
Sep-19-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN) (GlobeNewswire) +5.16% -6.13%
Sep-05-23 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Sep-04-23 03:04PM	3 Small-Cap Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Aug-24-23 08:00AM	Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome (GlobeNewswire) +5.41%
Aug-15-23 01:54AM	Q2 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:02AM	Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results (GlobeNewswire) +188.23%
07:00AM	Taysha Gene Therapies Announces $150 Million Private Placement Financing (GlobeNewswire)
Jul-31-23 08:00AM	Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome (GlobeNewswire)
Jul-18-23 07:08AM	Taysha Gene Therapies Insiders Added US$3.0m Of Stock To Their Holdings (Simply Wall St.)
Jun-28-23 08:00AM	Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day (GlobeNewswire)
Jun-15-23 08:00AM	Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome (GlobeNewswire)
Jun-05-23 08:00AM	Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome (GlobeNewswire) +5.06%
May-19-23 12:54PM	Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate (Benzinga) +5.64%
08:00AM	Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-16-23 11:41AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 10:15AM	Q1 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) -5.30%
May-11-23 04:01PM	Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.47%
May-04-23 08:00AM	Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11 (GlobeNewswire) +5.20%
Apr-27-23 04:52PM	Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +16.10%
Apr-15-23 08:24AM	Even after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past year (Simply Wall St.)
Mar-30-23 06:08AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Call Transcript (Insider Monkey) +11.37%
Mar-28-23 04:01PM	Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.19%
Mar-15-23 04:01PM	Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28 (GlobeNewswire) -10.17%
Feb-14-23 05:32PM	How patients' families pushed rare-disease therapy to cusp of clinical trial until biotech's cash halted progress (American City Business Journals)
Feb-08-23 05:42AM	A Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider increased their holdings by 28% last year (Simply Wall St.)
Jan-31-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook (GlobeNewswire) +6.49% -26.22%
Jan-24-23 02:32PM	Biotech signals potential pullback from 200-job Durham plant (American City Business Journals)
Dec-19-22 02:05PM	Dallas-based Taysha Gene Therapies names board chair as new CEO (American City Business Journals) -9.35%
Dec-16-22 06:19PM	Taysha Gene Therapies Announces Executive Leadership Changes (GlobeNewswire) -6.96%
Dec-01-22 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-29-22 04:01PM	Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-08-22 07:00AM	Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.00%
Nov-03-22 08:26PM	These 2 Stocks May Be Reaching a Bottom; Insiders Are Buying the Dip (TipRanks) +11.43%
Nov-02-22 07:00AM	Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8 (GlobeNewswire)
Oct-26-22 07:54PM	Taysha Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -27.52% -20.83%
11:05AM	3 Small-Cap Stocks That Hold Plenty of Promise Heading Into 2023 (TheStreet.com)
06:13AM	Positive week for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) institutional investors who lost 82% over the past year (Simply Wall St.)
Oct-25-22 04:01PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock (GlobeNewswire) +97.35%
03:55PM	Dallas-based Taysha Gene Therapies to receive $50M investment from Japanese pharmaceutical company (American City Business Journals)
09:31AM	Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? (PR Newswire)
08:15AM	Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs (Benzinga)

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	10% Owner	Jun 27 '24	Buy	2.25	1,333,333	2,999,999	1,333,333	Jul 01 08:00 AM
Manning Paul B	10% Owner	Nov 17 '23	Buy	1.63	100,000	163,000	16,566,667	Nov 20 07:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TSHA

Taysha Gene Therapies Inc

Upgrade your FINVIZ experience